• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Drug Makers Shifting Towards Targeted Cancer Drugs


The continuing shift away from one-size-fits-all cancer treatments will be on display this week when a medical society releases clinical data for drugs that target unique molecular features of cancer cells.





Pfizer Inc. , GlaxoSmithKline PLC (GSK, GSK.LN) and Johnson & Johnson are among those whose drugs will be highlighted when the American Society of Clinical Oncology on Wednesday releases summaries of more than 4,500 cancer studies, two weeks ahead of ASCO's annual scientific meeting.

Read the full story: http://hcp.lv/L7lWOL

Source: Market Watch (The Wall Street Journal)

Related Videos
Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"
Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"
Video 1 - "Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers"
Landman family
Video 10 - "Evolution of Auto-Substitution in Biosimilar Landscape"
Related Content
© 2023 MJH Life Sciences
All rights reserved.